Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03347279 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

A Phase 3 study of Asthma, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
1,061
Enrollment target
20
Study locations

NCT03347279: Completed Phase 3 study of Asthma, sponsored by AstraZeneca.

NCT03347279 is a Phase 3 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 1,061 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03347279, a Phase 3 study of Asthma, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
1,061 participants
Enrollment target
20
Study locations

Study Summary

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma

Primary Outcome

The annual exacerbation rate is based on unadjudicated exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set)

Conditions Studied

Interventions

  • OTHER Placebo
  • BIOLOGICAL Experimental: Tezepelumab

Study Locations (20)

California

  • Research Site - Bakersfield
  • Research Site - Encinitas
  • Research Site - Huntington Beach
  • Research Site - Long Beach
  • Research Site - Los Angeles
  • Research Site - Mission Viejo
  • Research Site - Newport Beach
  • Research Site - Northridge
  • Research Site - Palm Desert
  • Research Site - Rolling Hills Estates
  • Research Site - Walnut Creek
  • Research Site - Westminster

Alabama

  • Research Site - Dothan
  • Research Site - Foley

Arizona

  • Research Site - Gilbert
  • Research Site - Tucson

Florida

  • Research Site - Celebration
  • Research Site - Kissimmee

Colorado

  • Research Site - Denver

Connecticut

  • Research Site - New Haven

Trial Details

FieldValue
Enrollment Target 1,061 participants
Start Date 2017-11-23
Est. Completion 2020-11-12
Phase Phase 3
AstraZeneca

1,285 total trials

What the finished NCT03347279 record still lists

NCT03347279 is an interventional study that assigns participants to a tested intervention. Its 1,061 participants enrollment target places it among the larger protocols in the corpus, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (32% lower).

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03347279 names 20 study sites across 6 states, led by California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT03347279 about?

NCT03347279 is a clinical study titled "Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma". A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma

What is the current status of trial NCT03347279?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,061 participants. The study started on 2017-11-23. Estimated completion is 2020-11-12.

What conditions does trial NCT03347279 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT03347279?

The interventions under investigation include: Placebo (OTHER), Experimental: Tezepelumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT03347279?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03347279 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03347279's enrollment target sits among peer trials

1,061 39th of 374 higher than 336 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05520762 · 1,060 participants · NA

    Hospital Airway Resuscitation Trial

  • NCT05911568 · 1,060 participants

    Treatment With Endovascular Intervention for STroke Patients With Existing Disability

  • NCT07140172 · 1,060 participants · NA

    Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

  • NCT05125302 · 1,059 participants · Phase 3

    Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03347279, the US trial registry maintained by the National Library of Medicine. NCT03347279 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.